Headquarters


Grünenthal Group
Zieglerstraße 6
52078 Aachen
Germany

Phone: +49 241 569-0

Contact Form

Adverse Drug Reaction Reporting

 

 

Innovating at Scale: Gabriel Baertschi Interview Economist Intelligence Unit


In an interview with the Economist Intelligence Unit our CEO talks about Grünenthal’s ambition, explains why it is necessary to go for a network based approach in R&D and what his concept of leadership is all about.

Grünenthal Clinical Trial Portal

Grünenthal Group


The Grünenthal Group

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation.

Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a €2 billion company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.

Read more...


The E-G-G winners 2016

Cutting edge science in pain treatment in order to improve patients’ lives

The European Pain Federation EFIC® in cooperation with the pharmaceutical company Grünenthal announced that six young research scientists in the field of pain will be awarded an EFIC-GRÜNENTHAL Grant (E-G- G). This biennial grant, totalling € 200,000, supports up-and-coming pain scientists in translating their experimental project ideas into funded pain research projects.

Read more...